Protocol Number: CR109236
Primary Investigator: Thomas Aaberg Jr., M.D.
Janssen Research & Development, LLC has begun a study called CR109236 to evaluate the change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control. This study is a Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD).
Please click here for more detailed clinical information on the study.